Abstract
MicroRNAs (miRNAs) are de-regulated in cancer versus the normal tissue counterpart and actively participate in human carcinogenesis. Among the genes whose expression is under their control there are both oncogenes and tumor suppressor genes, revealing that it is not only limiting but simply wrong to assign them a function just as oncogenes or as tumor suppressor genes. In addition to primary tumors, miRNAs can be detected in almost all human body fluids and effectively help to diagnose cancer and to prognosticate clinical outcome and response to treatment of tumors. The advent of miRNA mimic and miRNA silencing molecules has allowed to modulate miRNA expression in tumors, showing that miRNAs can be effectively used as therapeutic agents. This review will focus on those findings that have provided the rationale for the use of miRNAs as patient “tailored” anti-cancer agents.
Keywords: Biomarker, cancer, drug resistance, microRNA, oncogene, therapy, tumor suppressor gene.
Current Molecular Medicine
Title:MicroRNAs and Cancer: Towards a Personalized Medicine
Volume: 13 Issue: 5
Author(s): M. Fabbri
Affiliation:
Keywords: Biomarker, cancer, drug resistance, microRNA, oncogene, therapy, tumor suppressor gene.
Abstract: MicroRNAs (miRNAs) are de-regulated in cancer versus the normal tissue counterpart and actively participate in human carcinogenesis. Among the genes whose expression is under their control there are both oncogenes and tumor suppressor genes, revealing that it is not only limiting but simply wrong to assign them a function just as oncogenes or as tumor suppressor genes. In addition to primary tumors, miRNAs can be detected in almost all human body fluids and effectively help to diagnose cancer and to prognosticate clinical outcome and response to treatment of tumors. The advent of miRNA mimic and miRNA silencing molecules has allowed to modulate miRNA expression in tumors, showing that miRNAs can be effectively used as therapeutic agents. This review will focus on those findings that have provided the rationale for the use of miRNAs as patient “tailored” anti-cancer agents.
Export Options
About this article
Cite this article as:
Fabbri M., MicroRNAs and Cancer: Towards a Personalized Medicine, Current Molecular Medicine 2013; 13 (5) . https://dx.doi.org/10.2174/1566524011313050006
DOI https://dx.doi.org/10.2174/1566524011313050006 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy
Current Drug Metabolism Raman Molecular Imaging of Cells and Tissues: Towards Functional Diagnostic Imaging Without Labeling
Current Pharmaceutical Biotechnology Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery The Adenine Nucleotide Translocator: A New Potential Chemotherapeutic Target
Current Drug Targets Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Current Cancer Drug Targets TRICOM Vector Based Cancer Vaccines
Current Pharmaceutical Design Quantitative Analysis of UGT2B28 mRNA Expression by Real-Time RT-PCR and Application to Human Tissue Distribution Study
Drug Metabolism Letters RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy Lipid Management for the Prevention of Cardiovascular Disease
Current Pharmaceutical Design Cancer-Homing Toxins
Current Pharmaceutical Design Proline Oxidase (POX) as A Target for Cancer Therapy
Current Drug Targets Antisense Treatment in Human Prostate Cancer and Melanoma
Current Cancer Drug Targets Cytochrome P450 2W1 (CYP2W1) in Colorectal Cancers
Current Cancer Drug Targets GCPII Imaging and Cancer
Current Medicinal Chemistry Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Mechanisms of Resistance to Photodynamic Therapy
Current Medicinal Chemistry Strategies and Techniques for Multi-Component Drug Design from Medicinal Herbs and Traditional Chinese Medicine
Current Topics in Medicinal Chemistry Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design Looking at Drug Resistance Mechanisms for Microtubule Interacting Drugs: Does TUBB3 Work?
Current Cancer Drug Targets